2. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med, 2006, 355(14): 1456-1465.
Abstract 666:针对伴单纯5q缺失的骨髓增生异常综合征(MDS-del(5q))的新预后评分系统(IPSS-del(5q)) 标题:Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q)) 作者:...
12. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-65. 13. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk my...
Among the multiple morphological subtypes, MDS with deletion of chromosome 5q (del(5q)) is of particular interest because of its distinct hematologic phenotype and exceptional therapeutic sensitivity to lenalidomide. Instead of homozygous inactivation, haploinsufficiency is sufficient to account for much ...
MDS伴特定遗传学异常包括:骨髓增生异常肿瘤伴低原始细胞和孤立5q缺失(MDS with low blasts and isolated 5q deletion, MDS-5q)、骨髓增生异常肿瘤伴低原始细胞和SF3B1突变(MDS with low blasts andSF3B1mutation, MDS-SF3B1)、骨髓增生异常肿瘤伴TP53双等位基因失活(MDS with biallelic TP53 inactivation, MDS-bi...
Summary. Abnormalities of chromosome 5 and 7 are frequently found in primary MDS. Cases with familial monosomy 7 are well recognized, but there are no reports of familial MDS with deletion of 5q. We describe two sisters, aged 38 and 36 years, both of whom had MDS and interstitial deletion...
或细胞原癌基因发生突变或细胞原癌基因发生突变- 经常接触苯、化疗药物、放射线等经常接触苯、化疗药物、放射线等Known molecular abnormalities in MDSGene Type of anomalyIncidence (%)RASPoint mutation (codon 12, 13 or 61)10-30%P53Point mutation or deletion of other allele5FMS(encodes M-CSF receptor)...
Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experienceDeletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experienceInterstitial lung diseaseMyelody...
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465. Article CAS Google Scholar Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and ...
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval ... FL Bras,M Sebert,C Kelaidi,...